Amgen Inc (AMGN)

154.80
1.32 0.85
NASDAQ : Health Care
Prev Close 156.12
Open 155.14
Day Low/High 153.53 / 156.12
52 Wk Low/High 130.09 / 181.81
Volume 3.40M
Avg Volume 4.19M
Exchange NASDAQ
Shares Outstanding 743.92M
Market Cap 116.14B
EPS 9.20
P/E Ratio 13.80
Div & Yield 4.60 (2.90%)

Latest News

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

5 Stocks Set to Rocket Higher

5 Stocks Set to Rocket Higher

Looks like these five stocks could rocket higher.

5 Rocket Stocks for 2017 -- Amgen, eBay, More

5 Rocket Stocks for 2017 -- Amgen, eBay, More

These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.

Amgen And Immatics Enter Strategic Collaboration To Develop Novel Bispecific Cancer Immunotherapies

Amgen And Immatics Enter Strategic Collaboration To Develop Novel Bispecific Cancer Immunotherapies

Arrangement Combines Immatics' XPRESIDENT® Technology and Amgen's Proprietary Bispecific Antibody Platform

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.

Dow Rises but Can't Reach 20,000 Milestone; S&P 500, Nasdaq Close at New Highs

Dow Rises but Can't Reach 20,000 Milestone; S&P 500, Nasdaq Close at New Highs

Dow 20,000 came agonizingly close on Friday, but building momentum flagged in the final moments of the trading session.

Dow Teases Wall Street With 20,000 Milestone but Backs Off

Dow Teases Wall Street With 20,000 Milestone but Backs Off

The Dow Jones Industrial Average backs away from its 20,000 milestone again on Friday after coming within a point of the level earlier in the session.

Here's Why Teva Shares Are Plummeting

Here's Why Teva Shares Are Plummeting

Shares fall on worse-than-expected guidance. It was not a good day for Teva Pharmaceuticals.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Stocks Go Green as Wall Street Processes Slower Jobs Growth

Stocks Go Green as Wall Street Processes Slower Jobs Growth

Stocks rise Friday, though unsettled trading made gains uncertain, after wage growth in December raises the chances for a few rate hikes this year.

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View

The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.

Stock Futures Turn Higher After U.S. Adds 156,000 Jobs in December

Stock Futures Turn Higher After U.S. Adds 156,000 Jobs in December

Stock futures turn higher Friday after the Labor Department says the U.S. added 156,000 jobs in December.

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

Amgen Establishes a Bottom and Signals It's Time to Buy

Amgen Establishes a Bottom and Signals It's Time to Buy

Traders could buy a dip to $150 if available or they can buy strength above $155, which ever comes first.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

U.S. stock futures trade slightly lower Friday ahead of the U.S. jobs report for December, the last under the Obama presidency.

Sanofi Investors Have Worst Day in Six Months

Sanofi Investors Have Worst Day in Six Months

Praluent Infringes on Amgen's patents for rival drug, Repatha, a ruling says.

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

Investor Nerves Are Beginning to Show

What's more, the number of new highs on the Nasdaq is down sharply from a month ago -- not an encouraging sign.

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Congressional Republicans who scrapped plans to overhaul the Office of Congressional Ethics might be regretting their decision. Senate Dems are asking for an investigation into HHS pick Tom Price.